ATE476502T1 - Recombinant modifiziertes plasmin - Google Patents

Recombinant modifiziertes plasmin

Info

Publication number
ATE476502T1
ATE476502T1 AT05737862T AT05737862T ATE476502T1 AT E476502 T1 ATE476502 T1 AT E476502T1 AT 05737862 T AT05737862 T AT 05737862T AT 05737862 T AT05737862 T AT 05737862T AT E476502 T1 ATE476502 T1 AT E476502T1
Authority
AT
Austria
Prior art keywords
domain
recombinant modified
terminal
human plasminogen
polypeptide
Prior art date
Application number
AT05737862T
Other languages
English (en)
Inventor
Jennifer Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Application granted granted Critical
Publication of ATE476502T1 publication Critical patent/ATE476502T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05737862T 2004-04-22 2005-04-21 Recombinant modifiziertes plasmin ATE476502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
PCT/US2005/013562 WO2005105990A2 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
ATE476502T1 true ATE476502T1 (de) 2010-08-15

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05737862T ATE476502T1 (de) 2004-04-22 2005-04-21 Recombinant modifiziertes plasmin

Country Status (27)

Country Link
US (2) US8034913B2 (de)
EP (2) EP1740698B1 (de)
JP (1) JP5026254B2 (de)
KR (1) KR101161819B1 (de)
CN (2) CN102660564B (de)
AT (1) ATE476502T1 (de)
AU (1) AU2005238464B2 (de)
BR (1) BRPI0510063B8 (de)
CA (1) CA2563675C (de)
CY (1) CY1111650T1 (de)
DE (1) DE602005022692D1 (de)
DK (1) DK1740698T3 (de)
EA (1) EA010784B1 (de)
ES (2) ES2349555T3 (de)
HR (1) HRP20100568T1 (de)
IL (1) IL178343A (de)
MA (1) MA28590B1 (de)
MX (1) MXPA06012236A (de)
NO (1) NO338542B1 (de)
NZ (1) NZ550250A (de)
PL (2) PL2246417T3 (de)
PT (2) PT1740698E (de)
RS (1) RS51623B (de)
SI (1) SI1740698T1 (de)
TN (1) TNSN06332A1 (de)
WO (1) WO2005105990A2 (de)
ZA (1) ZA200608498B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938427A (zh) 2004-02-11 2007-03-28 比奥莱克斯公司 纤溶酶原和微纤溶酶原在浮萍中的表达
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin
UA103771C2 (ru) 2008-06-04 2013-11-25 Грифолз Терапьютикс Инк. Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
RU2432397C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
RU2432396C2 (ru) * 2009-11-24 2011-10-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
JP2019500426A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
CN108210904A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗动脉粥样硬化及其并发症的药物及其用途
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
KR20230005298A (ko) 2020-05-11 2023-01-09 탈렌젠 인터내셔널 리미티드 척수성 근위축증의 치료 방법 및 약물
CA3196851A1 (en) 2020-11-25 2022-06-02 Grifols Worldwide Operations Limited Wound healing
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
EP4557949A1 (de) 2022-07-22 2025-05-28 Grifols Worldwide Operations Limited Stabile plasminzusammensetzungen zur organkonservierung und -wiederaufbereitung
WO2025235230A1 (en) * 2024-05-07 2025-11-13 The Scripps Research Institute Engineered plasmin molecules and related compositions for treating thrombosis
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
CA2243560A1 (en) 1996-01-23 1997-07-31 Rapigene, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
JPH10158300A (ja) * 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
NZ501774A (en) * 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
WO2000003726A1 (en) 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
ES2276536T3 (es) * 1998-09-29 2007-06-16 LEUVEN RESEARCH & DEVELOPMENT VZW Uso de compuestos que reducen las alfas2-antiplasminas in vivo para la preparacion de una composicion para el tratamiento del ictus isquemico.
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6969515B2 (en) * 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6664112B2 (en) 2000-06-02 2003-12-16 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
PT1343903E (pt) * 2000-12-21 2008-02-18 Thrombogenics Nv ''um vector de expressão de levedura e um método de produção de uma proteína recombinante por expressão numa célula de levedura
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US8231869B2 (en) 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
MXPA06012236A (es) 2007-01-31
EP2246417B1 (de) 2015-01-21
WO2005105990A2 (en) 2005-11-10
ES2349555T3 (es) 2011-01-05
PT2246417E (pt) 2015-05-05
PL1740698T3 (pl) 2011-01-31
NO338542B1 (no) 2016-09-05
HK1150242A1 (en) 2011-11-11
CY1111650T1 (el) 2015-10-07
CA2563675C (en) 2012-08-28
SI1740698T1 (sl) 2010-11-30
CN102660564A (zh) 2012-09-12
NZ550250A (en) 2009-05-31
ES2534744T3 (es) 2015-04-28
CN1961070A (zh) 2007-05-09
EA200601950A1 (ru) 2007-02-27
MA28590B1 (fr) 2007-05-02
EA010784B1 (ru) 2008-10-30
DE602005022692D1 (de) 2010-09-16
KR20070006918A (ko) 2007-01-11
EP1740698A2 (de) 2007-01-10
DK1740698T3 (da) 2010-10-25
US8420079B2 (en) 2013-04-16
CN102660564B (zh) 2013-05-08
EP1740698B1 (de) 2010-08-04
AU2005238464A1 (en) 2005-11-10
HRP20100568T1 (hr) 2010-11-30
BRPI0510063B8 (pt) 2021-05-25
JP5026254B2 (ja) 2012-09-12
HK1099341A1 (en) 2007-08-10
NO20065050L (no) 2006-11-03
HK1175812A1 (en) 2013-07-12
KR101161819B1 (ko) 2012-07-03
WO2005105990A3 (en) 2006-01-12
RS51623B (sr) 2011-08-31
US20110318812A1 (en) 2011-12-29
PL2246417T3 (pl) 2015-06-30
US8034913B2 (en) 2011-10-11
IL178343A (en) 2010-11-30
JP2007533327A (ja) 2007-11-22
IL178343A0 (en) 2007-02-11
US20100304465A1 (en) 2010-12-02
TNSN06332A1 (en) 2008-02-22
AU2005238464B2 (en) 2011-01-27
BRPI0510063A (pt) 2008-03-11
PT1740698E (pt) 2010-11-02
CA2563675A1 (en) 2005-11-10
EP2246417A1 (de) 2010-11-03
BRPI0510063B1 (pt) 2020-03-17
ZA200608498B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
CY1111650T1 (el) Ανασυνδυαστικα τροποποιημενη πλασμινη
NZ593837A (en) Recombinantly modified plasmin
Bode The structure of thrombin: a janus-headed proteinase
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
Hata et al. Domain II of m‐calpain is a Ca2+‐dependent cysteine protease
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
NZ588200A (en) Procoagulant peptides
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
ATE277172T1 (de) Rekombinante blutgerinnungsproteasen
TW200733970A (en) Recombinantly modified plasmin
Avilan et al. Interaction of Leishmania mexicana promastigotes with the plasminogen–plasmin system
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin, from the venom of Trimeresurus elegans (Sakishima-habu)
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
Castro et al. Current status of snake venom thrombin-like enzymes
EE05296B1 (et) Glkuronl-C5-epimeraas, seda kodeeriv DNA ja selle kasutamine
DE60336265D1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
WO2005037202A3 (en) Methods for modulating angiogenesis
Amoozegari et al. Purification of blood coagulation factor V activator from the venom of Iranian Vipera lebetina
ATE460476T1 (de) Menschliche protein phosphatase mit ef-hände-1 (ppef-1)- ähnliches genvariant assoziert mit t- zellen lymphoblastisches lymphom

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1740698

Country of ref document: EP